Food and Drug Administration Commissioner Marty Makary has resigned, marking a significant leadership shakeup within President Donald Trump's second-term health team. The announcement, made on Tuesday, comes as the agency continues to navigate ongoing uncertainty over regulatory priorities and internal operations.
"Well, I don’t want to say, but Marty’s a great guy, he’s a friend of mine, he’s a wonderful man and he’s going to be off. He was having some difficulty." — President Donald Trump, President of the United States
Makary, a Johns Hopkins surgeon who gained national attention during pandemic-era health policy debates, was appointed by President Trump and confirmed by the Senate in March 2025. His selection was widely seen as part of a broader administrative effort to reshape federal health agencies following years of political conflict over COVID-19-era mandates, vaccine policy, and public trust in health institutions, according to Trending Politics.
However, Makary's tenure soon encountered internal pushback regarding the FDA's approach to regulatory oversight. A central tension point involved how the agency should balance its traditional caution with calls for faster approvals, particularly in politically sensitive areas of public health policy. This dynamic created friction within the agency as it sought to define its direction.
President Trump acknowledged Makary’s departure while speaking to reporters on Tuesday. “Well, I don’t want to say, but Marty’s a great guy, he’s a friend of mine, he’s a wonderful man and he’s going to be off,” President Trump said, according to The Hill. “He was having some difficulty.” This statement hinted at underlying challenges that may have contributed to the Commissioner's decision to step down.
Another significant source of tension during Makary’s time involved abortion-related drug oversight. The FDA faced scrutiny from various advocacy groups over its handling of mifepristone reviews and broader regulatory decisions tied to reproductive health policy. This issue, a highly contentious area in national politics, placed additional pressure on the agency's leadership and decision-making processes.
According to Politico, Makary also faced pressure from multiple directions, including criticism from industry stakeholders and political advocates. These groups reportedly argued that the agency’s decision-making process had slowed amid internal restructuring efforts. Reports also pointed to staffing turnover and management disputes as contributing factors to broader instability within the FDA, suggesting a challenging operational environment for the Commissioner.
Makary had been scheduled to testify before a Senate Appropriations subcommittee this week on FDA budget matters. During the anticipated hearing, lawmakers were expected to question agency priorities, including drug approval timelines and regulatory consistency, underscoring the ongoing scrutiny of the FDA's performance and direction. His unexpected resignation preempts this testimony.
The departure of Commissioner Makary adds to a wider pattern of personnel changes observed across federal health agencies during President Trump’s second term. The administration has continued its efforts to reshape leadership within the Department of Health and Human Services and revisit regulatory priorities across multiple divisions. Officials have signaled an interest in both tightening oversight of drug approvals and accelerating review timelines for certain categories of medical products, indicating a complex and potentially conflicting set of objectives for the FDA.
Supporters of Makary have often highlighted his willingness to challenge long-standing regulatory practices as evidence of reform efforts inside the agency. They suggest his approach aimed to modernize the FDA and make it more responsive. Conversely, critics argue that during his tenure, the FDA struggled to maintain consistency and a clear direction, attributing these issues to the internal disagreements and external pressures he faced. These competing perspectives reflect broader divisions in national health policy debates that have intensified since the pandemic.
Following Makary's resignation, FDA Deputy Commissioner for Food Kyle Diamantas is expected to serve as acting commissioner. The White House will now weigh a permanent replacement to lead the agency through its next phase of policy implementation. President Trump emphasized the importance of the position, noting its significance within the administration’s broader health agenda. “Everybody wants that job. It’s a very important job,” he stated. The search for a new commissioner will undoubtedly be closely watched, given the critical role the FDA plays in public health and the economy.
